Faron has terminated the liquidity providing agreement with Lago Kapital TURKU, FI / ACCESS Newswire / May 6, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage ...

Faron Pharmaceuticals, a clinical-stage biopharmaceutical company based in Finland, has announced that it has treated 255 patients with its experimental bexmarilimab (bex) treatment, which helps the ...

TURKU, FI / ACCESS Newswire / May 4, 2026 / The annual general meeting ("AGM") of Faron Pharmaceuticals Ltd (LSE:FARN)(First North:FARON) took place in Turku, Finland, today 4 May 2026. Thirty-nine ...

Strategic collaboration with a leading global CRO supports disciplined trial execution and operational efficiency, advancing Faron's mission to provide treatment for patients with HR-MDS TURKU, FI / ...

TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based ...

Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, ...

In a year already marked by critical scientific milestones, Faron Pharmaceuticals is set to take center stage once again. The clinical-stage biopharmaceutical company has announced that detailed Phase ...

Faron Pharmaceuticals has pointed to the latest snapshot of early-stage data as proof that its tumor-associated macrophage candidate bexmarilimab is ready to enter phase 2 trials this year. The ...

Faron Pharmaceuticals has zeroed in on low levels of interferon-beta bioactivity to explain why its phase 3 traumakine trial failed comprehensively. The biotech is now testing product batches to ...